• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿片类药物引起的肠道功能障碍:患病率、病理生理学及负担

Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden.

作者信息

Panchal S J, Müller-Schwefe P, Wurzelmann J I

机构信息

National Institute of Pain and Coalition for Pain Education Foundation, Tampa, FL 33558, USA.

出版信息

Int J Clin Pract. 2007 Jul;61(7):1181-7. doi: 10.1111/j.1742-1241.2007.01415.x. Epub 2007 May 4.

DOI:10.1111/j.1742-1241.2007.01415.x
PMID:17488292
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1974804/
Abstract

As a result of the undesired action of opioids on the gastrointestinal (GI) tract, patients receiving opioid medication for chronic pain often experience opioid-induced bowel dysfunction (OBD), the most common and debilitating symptom of which is constipation. Based on clinical experience and a comprehensive MEDLINE literature review, this paper provides the primary care physician with an overview of the prevalence, pathophysiology and burden of OBD. Patients with OBD suffer from a wide range of symptoms including constipation, decreased gastric emptying, abdominal cramping, spasm, bloating, delayed GI transit and the formation of hard dry stools. OBD can have a serious negative impact on quality of life (QoL) and the daily activities that patients feel able to perform. To relieve constipation associated with OBD, patients often use laxatives chronically (associated with risks) or alter/abandon their opioid medication, potentially sacrificing analgesia. Physicians should have greater appreciation of the prevalence, symptoms and burden of OBD. In light of the serious negative impact OBD can have on QoL, physicians should encourage dialogue with patients to facilitate optimal symptomatic management of the condition. There is a pressing need for new therapies that act upon the underlying mechanisms of OBD.

摘要

由于阿片类药物对胃肠道产生不良作用,接受阿片类药物治疗慢性疼痛的患者常出现阿片类药物引起的肠道功能障碍(OBD),其中最常见且使人虚弱的症状是便秘。基于临床经验和全面的MEDLINE文献综述,本文为初级保健医生提供了OBD的患病率、病理生理学及负担的概述。OBD患者会出现多种症状,包括便秘、胃排空减慢、腹部绞痛、痉挛、腹胀、肠道传输延迟以及干结硬便的形成。OBD会对生活质量(QoL)以及患者自认为能够进行的日常活动产生严重负面影响。为缓解与OBD相关的便秘,患者常长期使用泻药(存在风险)或改变/停用阿片类药物,这可能会牺牲镇痛效果。医生应更深入了解OBD的患病率、症状及负担。鉴于OBD会对QoL产生严重负面影响,医生应鼓励与患者进行沟通,以促进对该病症的最佳症状管理。迫切需要针对OBD潜在机制的新疗法。

相似文献

1
Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden.阿片类药物引起的肠道功能障碍:患病率、病理生理学及负担
Int J Clin Pract. 2007 Jul;61(7):1181-7. doi: 10.1111/j.1742-1241.2007.01415.x. Epub 2007 May 4.
2
Incidence, prevalence, and management of opioid bowel dysfunction.阿片类药物所致肠道功能障碍的发病率、患病率及管理
Am J Surg. 2001 Nov;182(5A Suppl):11S-18S. doi: 10.1016/s0002-9610(01)00782-6.
3
Palliative care and pain: new strategies for managing opioid bowel dysfunction.姑息治疗与疼痛:处理阿片类药物所致肠道功能障碍的新策略
J Palliat Med. 2008 Sep;11 Suppl 1:S1-19; quiz S21-2. doi: 10.1089/jpm.2008.9839.supp.
4
The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1).阿片类药物引起的肠道功能障碍的患病率、严重程度及影响:一项美国和欧洲患者调查(PROBE 1)的结果
Pain Med. 2009 Jan;10(1):35-42. doi: 10.1111/j.1526-4637.2008.00495.x. Epub 2008 Aug 18.
5
Lubiprostone for the treatment of opioid-induced bowel dysfunction.鲁比前列酮治疗阿片类药物引起的肠道功能障碍。
Expert Opin Pharmacother. 2011 Apr;12(6):983-90. doi: 10.1517/14656566.2011.566559. Epub 2011 Mar 9.
6
Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial.阿洛司琼:一种口服的、外周作用的μ阿片受体拮抗剂,用于治疗阿片类药物引起的肠道功能障碍——一项为期21天的治疗随机临床试验。
J Pain. 2005 Mar;6(3):184-92. doi: 10.1016/j.jpain.2004.12.001.
7
Management of opioid-induced bowel dysfunction in cancer patients.癌症患者阿片类药物引起的肠道功能障碍的管理。
Support Care Cancer. 2004 Sep;12(9):613-8. doi: 10.1007/s00520-004-0649-7.
8
Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain.阿洛司琼,一种用于治疗阿片类药物引起的肠功能障碍的外周作用μ-阿片受体(PAM-OR)拮抗剂:一项针对因慢性非癌性疼痛服用阿片类药物的受试者的随机、双盲、安慰剂对照、剂量探索研究结果。
Pain. 2008 Jul 15;137(2):428-440. doi: 10.1016/j.pain.2007.11.008. Epub 2007 Dec 31.
9
Opioid-related bowel dysfunction: prevalence and identification of predictive factors in a large sample of Italian patients on chronic treatment.阿片类药物相关性肠功能紊乱:在意大利慢性治疗的大量患者中,其流行率和预测因素的识别。
Eur Rev Med Pharmacol Sci. 2010 Dec;14(12):1045-50.
10
A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.一项随机、安慰剂对照的 3 期试验(研究 SB-767905/012),评估 alvimopan 治疗非癌症疼痛患者阿片类药物引起的肠道功能障碍。
J Pain. 2011 Feb;12(2):185-93. doi: 10.1016/j.jpain.2010.06.012.

引用本文的文献

1
A short-duration telementoring pain management programme for Medicaid: impact on clinician outcomes.一项针对医疗补助计划的短期远程指导疼痛管理项目:对临床医生结果的影响
Health Educ Res. 2025 May 15;40(3). doi: 10.1093/her/cyaf019.
2
Opioid-induced Constipation: Old and New Concepts in Diagnosis and Treatment.阿片类药物所致便秘:诊断与治疗的新旧概念
J Neurogastroenterol Motil. 2024 Apr 30;30(2):131-142. doi: 10.5056/jnm23144.
3
What a pain in the … back: a review of current treatment options with a focus on naproxen sodium.真是令人头疼:当前治疗选择的综述,重点是萘普生钠。
J Pharm Pharm Sci. 2024 Feb 7;27:12384. doi: 10.3389/jpps.2024.12384. eCollection 2024.
4
Impact of Patient Subgroups on the Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients with Advanced Illness.患者亚组对甲基纳曲酮治疗晚期疾病患者阿片类药物所致便秘的疗效和安全性的影响。
J Pain Res. 2023 Oct 20;16:3529-3543. doi: 10.2147/JPR.S416307. eCollection 2023.
5
Management of Constipation in Hospitalized Patients.住院患者便秘的管理
J Clin Med. 2023 Sep 23;12(19):6148. doi: 10.3390/jcm12196148.
6
Iatrogenic Side Effects of Pain Therapies.疼痛治疗的医源性副作用
Cureus. 2023 Sep 2;15(9):e44583. doi: 10.7759/cureus.44583. eCollection 2023 Sep.
7
Efficacy and Safety of Naloxegol in Patients with Chronic Non-Cancer Pain Who Experience Opioid-Induced Constipation: A Pooled Analysis of Two Global, Randomized Controlled Studies.纳洛西醇用于治疗阿片类药物引起便秘的慢性非癌性疼痛患者的疗效与安全性:两项全球随机对照研究的汇总分析
J Pain Res. 2023 Aug 28;16:2943-2953. doi: 10.2147/JPR.S417045. eCollection 2023.
8
Methylnaltrexone Treatment for Opioid-Induced Constipation in Patients with and without Cancer: Effect of Initial Dose.甲基纳曲酮治疗癌症患者和非癌症患者阿片类药物引起的便秘:初始剂量的效果
J Pain Res. 2023 Jul 27;16:2595-2607. doi: 10.2147/JPR.S405825. eCollection 2023.
9
Risk Factors for Postoperative Ileus Following Spine Surgery: A Systematic Review With Meta-Analysis.脊柱手术后肠梗阻的危险因素:一项荟萃分析的系统评价
Global Spine J. 2024 Mar;14(2):707-717. doi: 10.1177/21925682231174192. Epub 2023 May 2.
10
Pre-existing Opioid Use Worsens Outcomes in Patients With Diverticulitis.既往使用阿片类药物会使憩室炎患者的预后恶化。
Cureus. 2023 Feb 4;15(2):e34624. doi: 10.7759/cureus.34624. eCollection 2023 Feb.

本文引用的文献

1
Treatment of opioid-induced gut dysfunction.阿片类药物引起的肠道功能障碍的治疗。
Expert Opin Investig Drugs. 2007 Feb;16(2):181-94. doi: 10.1517/13543784.16.2.181.
2
Management of common opioid-induced adverse effects.常见阿片类药物所致不良反应的管理
Am Fam Physician. 2006 Oct 15;74(8):1347-54.
3
Toward evidence-based prescribing at end of life: a comparative analysis of sustained-release morphine, oxycodone, and transdermal fentanyl, with pain, constipation, and caregiver interaction outcomes in hospice patients.迈向临终时的循证处方:对缓释吗啡、羟考酮和透皮芬太尼的比较分析,以及临终关怀患者的疼痛、便秘和护理人员互动结果
Pain Med. 2006 Jul-Aug;7(4):320-9. doi: 10.1111/j.1526-4637.2006.00184.x.
4
Opioid-induced gastrointestinal dysfunction.阿片类药物引起的胃肠功能障碍。
Dig Dis. 2006;24(1-2):105-12. doi: 10.1159/000090314.
5
Functional bowel disorders.功能性肠病
Gastroenterology. 2006 Apr;130(5):1480-91. doi: 10.1053/j.gastro.2005.11.061.
6
Treatment of gastroesophageal reflux disease.胃食管反流病的治疗
Pharm World Sci. 2005 Dec;27(6):432-5. doi: 10.1007/s11096-005-4798-7.
7
Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain.长期使用阿片类药物对慢性非恶性疼痛患者生活质量的影响。
Curr Med Res Opin. 2005 Oct;21(10):1555-68. doi: 10.1185/030079905X65321.
8
Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network.欧洲姑息治疗病房中的疼痛及疼痛治疗。来自欧洲姑息治疗协会研究网络的横断面调查。
Palliat Med. 2005 Sep;19(6):477-84. doi: 10.1191/0269216305pm1054oa.
9
The role of opioids in cancer pain.阿片类药物在癌症疼痛中的作用。
BMJ. 2005 Oct 8;331(7520):825-9. doi: 10.1136/bmj.331.7520.825.
10
Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids.慢性非恶性疼痛中阿片类药物不良事件的患病率:口服阿片类药物随机试验的系统评价
Arthritis Res Ther. 2005;7(5):R1046-51. doi: 10.1186/ar1782. Epub 2005 Jun 28.